CORPHED
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CORPHED (CORPHED).
Corbined (idarucizumab) is a humanized monoclonal antibody fragment that binds to dabigatran with high affinity, neutralizing its anticoagulant effect. It acts as a specific reversal agent for dabigatran.
| Metabolism | Idarucizumab is a monoclonal antibody fragment; it is degraded into small peptides and amino acids via catabolic pathways. No significant metabolism by CYP enzymes. |
| Excretion | Renal (70-80% as unchanged drug), biliary/fecal (20-30%) |
| Half-life | Terminal half-life 3-4 hours; prolonged in renal impairment (up to 15 hours) |
| Protein binding | 20-30% bound to albumin |
| Volume of Distribution | 1.5-2.0 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 65-75%; Intramuscular: 75-85% |
| Onset of Action | Oral: 30-60 minutes; Intramuscular: 10-15 minutes; Intravenous: <5 minutes |
| Duration of Action | Oral: 4-6 hours; Intramuscular: 4-5 hours; Intravenous: 2-4 hours |
10-20 mg orally twice daily; maximum 60 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-60 mL/min: 50% dose reduction; GFR <30 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: contraindicated. |
| Pediatric use | 0.3-0.5 mg/kg orally twice daily; maximum 40 mg/day. |
| Geriatric use | Initiate at 10 mg orally once daily, titrate cautiously to maximum 40 mg/day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CORPHED (CORPHED).
| Breastfeeding | Phenylephrine is excreted into breast milk in small amounts; the M/P ratio is approximately 0.2. While the relative infant dose is low (<2% of maternal weight-adjusted dose), systemic effects in the breastfeeding infant are possible due to its vasoconstrictive properties. Caution is advised, and alternative decongestants such as pseudoephedrine may be preferred during lactation. |
| Teratogenic Risk | CORPHED (phenylephrine) is classified as FDA Pregnancy Category C. In the first trimester, there is an increased risk of fetal malformations associated with maternal hypertension and reduced placental perfusion; animal studies have shown teratogenic effects at high doses. During the second and third trimesters, prolonged use may cause uteroplacental insufficiency, fetal hypoxia, and bradycardia. It is recommended to avoid use during pregnancy unless the benefit outweighs the risk. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Known hypersensitivity to idarucizumab or any component of the formulation."]
| Precautions | ["Thromboembolic risk: Reversal of anticoagulation may expose patients to thrombotic risk; consider reinitiating antithrombotic therapy when appropriate.","Hypersensitivity reactions: Monitor for infusion-related reactions."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate for hypertensive episodes or reflex bradycardia. Assess fetal heart rate during prolonged infusions for signs of fetal distress. In high-dose or continuous intravenous administration, monitor uterine contractility and placental perfusion. Watch for maternal symptoms of hypertension, headache, or arrhythmia. |
| Fertility Effects | There is no conclusive evidence that phenylephrine adversely affects human fertility. Animal studies do not suggest significant reproductive impairment. However, use in assisted reproductive technology (e.g., during oocyte retrieval) is limited due to vasoconstrictive effects on ovarian blood flow. Overall, no specific fertility precautions are required. |